In the study, 109 patients suffering from erectile dysfunction who were treated for 1–18 months by moclobemid with a daily dose of 150–600 mg are kathamnestically evaluated. Their average age was 49 y. (21–71 y.). The results of this treatment were always evaluated one month after the preparation had been given, namely according to the ability of reaching the same level of erection as before the inception of erectile dysfunction. The results is either „adjusted“ or „not adjusted“ (i. e. the patient did/did not reach the level of erection as before the inception of erectile dysfunction. 61% of the group (N=109) have been adjusted. A mostly psychogenically conditioned erectile dysfunction was found in 60% of patients (N=65), a mostly organically conditioned one in 40% (N=44). The infl uence of patients’ age on the length and result of treatment has turned out to be statistically insignifi cant. In mostly psychogenically conditioned erectile dysfunctions lasting 1–4 years, 74% of patients (N=40) were adjusted and also 55% (N=6) of those lasting 5–18 years. In mostly organically conditioned erectile dysfunctions lasting 1–4 years 58% (N=21) were adjusted and 42% (N=15) were without effect. In mostly organically conditioned ones lasting 5–18 years no patient has been adjusted (N=8). If the treatment by moclobemid is successful, 90% of these patients are adjusted in two months. Combination of moclobemid and yohimbine in the watched group did not appear to be more successful than moclobemid monotherapy. That results in the moclobemid treatment in erectile dysfunctions being indicated in: Psychogenical etiology of the diffi culties, duration up to 4 years (even in case of organic etiology). It is recommended for the treatment of unadjusted dysfunctions to continue if there are any signs of success of the treatment in two months from the beginning of therapy.

        Key words: moclobemid, erectile dysfunctions.